Oxidative stress and neuroinflammation in Alzheimer's disease and amyotrophic lateral sclerosis: Common links and potential therapeutic targets

Journal of Alzheimer's Disease

Volumn 6, Issue 2, 2004, Pages 147-157

  Mhatrea, Molina ^a,c   Floyd, Robert A ^a,b,c   Hensley, Kenneth ^a,c  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

ALS; Alzheimer's disease; Lipoxygenase; Microglia; Neuroinflammation; Protein oxidation; Tumor necrosis factor

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-39]; AMYLOID BETA PROTEIN[1-42]; ARACHIDONIC ACID; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; GAMMA INTERFERON; IBUPROFEN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 6; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; REACTIVE NITROGEN SPECIES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; ARACHIDONIC ACID METABOLISM; CELL ACTIVATION; CYTOKINE PRODUCTION; DISEASE MODEL; DRUG MECHANISM; DRUG TARGETING; GENETIC TRANSCRIPTION; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MICROGLIA; NEUROPATHOLOGY; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SENILE PLAQUE; STRESS; TREATMENT PLANNING;

EID: 2342417953     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/jad-2004-6206     Document Type: Review

References (111)

1. P.S. Aisen, K.A. Schafer, M. Grundman, E. Pfeiffer, M. Sano and K.L. Davis, Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial, JAMA 289 (2003), 2819-2826.
2. H. Akiyama, S. Barger, S. Barnum, B. Bradt, J. Bauer, G.M. Cole, N.R. Cooper, P. Eikelenboom, M. Emmerling, B.L. Fiebich, C.E. Finch, S. Frautschy, W.S. Griffin, H. Hampel, M. Hull, G. Landreth, L. Lue, R. Mrak, I.R. Mackenzie, P.L. McGeer, M.K. O'Banion, J. Pachter, G. Pasinetti, C. Plata-Salaman, J. Rogers, R. Rydel, Y. Shen, W. Streit, R. Strohmeyer, I. Tooyoma, F.L. Van Muiswinkel, R. Veerhuis, D. Walker, S. Webster, B. Wegrzyniak, G. Wenk and T. Wyss-Coray, Inflammation and Alzheimer's disease, Neurobiol Aging 21 (2000), 383-421.
3. L. Aloe, M. Fiore, L. Probert, P. Turrini and P. Tirassa, Overexpression of tumour necrosis factor alpha in the brain of transgenic mice differentially alters nerve growth factor levels and choline acetyltransferase activity, Cytokine 11 (1999), 45-54.
4. J.M. Andersen, O. Myhre, H. Aarnes, T.A. Vestad and F. Fonnum, Identification of the hydroxyl radical and other reactive oxygen species in human neutrophil granulocytes exposed to a fragment of the amyloid beta peptide, Free Radic Res 37 (2003), 269-279.
5. Y. Ando, T. Brannstrom, K. Uchida, N. Nyhlin, B. Nasman, O. Suhr, T. Yamashita, T. Olsson, M. El Salhy, M. Uchino and M. Ando, Histochemical detection of 4-hydroxynonenal protein in Alzheimer amyloid, J Neurol Sci 156 (1998), 172-176.
6. P.K. Andrus, T.J. Fleck, M.E. Gurney and E.D. Hall, Protein oxidative damage in a transgenic mouse model of familial amyotrophic lateral sclerosis, J Neurochem 71 (1998), 2041-2048.
7. F. Baskin, G.M. Smith, J.A. Fosmire and R.N. Rosenberg, Altered apolipoprotein E secretion in cytokine treated human astrocyte cultures, J Neurol Sci 148 (1997), 15-18.
8. N.G. Bazan, V. Colangelo and W.J. Lukiw, Prostaglandins and other lipid mediators in Alzheimer's disease, Prostaglandins Other Lipid Mediat 68-69 (2002), 197-210.
9. M.F. Beal, R.J. Ferrante, S.E. Browne, R.T. Matthews, N.W. Kowall and R.H. Brown Jr, Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis, Ann Neurol 42 (1997), 644-654.
10. I. Blasko, F. Marx, E. Steiner, T. Hartmann and B. Grubeck-Loebenstein, TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs, FASEB J 13 (1999), 63-68.
11. R.H. Brown, Jr. and W. Robberecht, Amyotrophic lateral sclerosis: pathogenesis, Semen Neurol 21 (2001), 131-139.
12. L.I. Bruijn, M.F. Beal, M.W. Becher, J.B. Schulz, RC. Wong, D.L. Price and D.W. Cleveland, Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant, Proc Natl Acad Sci USA 94 (1997), 7606-7611.
13. M. Buckwalter, J.P. Pepper, R.F. Gaertner, D. Von Euw, P. Lacombe and T. Wyss-Coray, Molecular and functional dissection of TGF-beta1-induced cerebrovascular abnormalities in transgenic mice, Ann N Y Acad Sci 977 (2002), 87-95.
14. C.C. Chao, S. Hu, W.H. Frey, T.A. Ala, W.W. Tourtellotte and P.K. Peterson, Transforming growth factor beta in Alzheimer's disease, Clin Diagn Lab Immunol 1 (1994), 109-110.
15. S. Chen, R.C. Frederickson and K.R. Brunden, Neuroglial-mediated immununoinflammatory responses in Alzheimer's disease: complement activation and therapeutic approaches, Neurobiol Aging 17 (1996), 781-787.
16. C.A. Colton and D.L. Gilbert, Production of superoxide anions by a CNS macrophage, the microglia, FEBS Lett 223 (1987), 284-288.
17. J.P. Crow, J.B. Sampson, Y. Zhuang, J.A. Thompson and J.S. Beckman, Decreased zinc affinity of amyotrophic lateral sclerosis-associated superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite, J Neurochem 69 (1997), 1936-1944.
18. S. Das and H. Potter, Expression of the Alzheimer amyloid-promoting factor antichymotrypsin is induced in human astrocytes by IL-1, Neuron 14 (1995), 447-456.
19. 2 forming NADPH oxidase in microglia, monocytes and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer's disease, J Biol Chem 274 (1999), 15493-15499.
20. P. Eikelenboom and F.C. Stam, Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study, Acta Neuropathol (Berl) 57 (1982), 239-242.
21. P. Eikelenboom and R. Veerhuis, The role of complement and activated microglia in the pathogenesis of Alzheimer's disease, Neurobiol Aging 17 (1996), 673-680.
22. J.L. Elliott, Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis, Brain Res Mol Brain Res 95 (2001), 172-178.
23. H. Fillit, W.H. Ding and L. Buee, Elevated circulating TNF levels in Alzheimer's disease, Neurosci Lett 129 (1991), 318-320.
24. S.A. Frautschy, W. Hu, P. Kim, S.A. Miller, T. Chu, M.E. Harris-White and G.M. Cole, Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology, Neurobiol Aging 22 (2001), 993-1005.
25. R.M. Friedlander, R.H. Brown, V. Gagliardini, J. Wang and J. Yuan, Inhibition of ICE slows ALS in mice, Nature 388 (1997), 31.
26. J.Y. Fu, J.L. Masferrer, K. Seibert, A. Raz and P. Needleman, The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes, J Biol Chem 265 (1990), 16737-16740.
27. C.D. Funk, Prostaglandins and leukotrienes: Advances in eicosanoid biology, Science 294 (2001), 1871-1875.
28. D. Goldgaber, H.W. Harris, T. Hla, T. Maciag, R.J. Donnelly, J.S. Jacobsen, M.P. Vitek and D.C. Gajdusek, Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells, Proc Natl Acad Sci USA 86 (1989), 7606-7610.
29. P.F. Good, P. Werner, A. Hsu, C.W. Olanow and D.P. Perl, Evidence of neuronal oxidative damage in Alzheimer's disease, Am J Pathol 149 (1996), 21-28.
30. W.S. Griffin, L.C. Stanley, C. Ling, L. White, V. MacLeod, L.J. Perrot, C.L. White 3rd and C. Araoz, Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease, Proc Natl Acad Sci USA 86 (1989), 7611-7615.
31. W.S. Griffin, J.G. Sheng, G.W. Roberts and R.E. Mrak, Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution, J Neuropathol Exp Neurol 54 (1995), 276-281.
32. J.T. Guo, J. Yu, D. Grass, F.C. de Beer and M.S. Kindy, Inflammation-dependent cerebral deposition of serum amyloid a protein in a mouse model of amyloidosis, J Neurosci 22 (2002), 5900-5909.
33. C.K. Hand and G.A. Rouleau, Familial amyotrophic lateral sclerosis, Muscle Nerve 25 (2002), 135-159.
34. J. Haas, B. Storch-Hagenlocher, A. Biessmann and B. Wildemann, Inducible nitric oxide synthase and argininosuccinate synthetase: co-induction in brain tissue of patients with Alzheimer's dementia and following stimulation with beta-amyloid 1-42 in vitro, Neurosci Lett 322 (2002), 121-125.
35. K. Hensley, J.M. Carney, M.P. Mattson, M. Aksenova, M. Harris, J.F. Wu, R.A. Floyd and D.A. Butterfield, A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease, Proc Natl Acad Sci USA 91 (1994), 3270-3274.
36. K. Hensley, J. Fedynychyn, S. Ferrel, R.A. Floyd, B. Gordon, P. Grammas, L. Hamdheydari, M. Mhatre, S. Mou, Q.N. Pye, C. Stewart, M. West, S. West and K. Williamson. Message and protein-level elevation of tumor necrosis factor α (TNFα) and TNFα-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis, Neurobiology of Disease (in press).
37. K. Hensley, R.A. Floyd, B. Gordon, S. Mou, Q.N. Pye, C.A. Stewart, M. West and K.S. Williamson, Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis, J Neurochem 82 (2002), 365-374.
38. K. Hensley, M.L. Maidt, Z. Yu, H. Sang, W.R. Markesbery and R.A. Floyd, Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation, J Neurosci 18 (1998), 8126-8132.
39. K. Hensley, T. Tabatabaie, C.A. Stewart, Q. Pye and R.A. Floyd, Nitric oxide and derived species as toxic agents in stroke, AIDS dementia, and chronic neurodegenerative disorders, Chem Res Taxicol 10 (1997), 527-532.
40. L. Ho, C. Pieroni, D. Winger, D.P. Purohit, P.S. Aisen and G.M. Pasinetti, Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease, J Neurosci Res 57 (1999), 295-303.
41. X. Huang, C.S. Atwood, M.A. Hartshorn, G. Multhaup, L.E. Goldstein, R.C. Scarpa, M.P. Cuajungco, D.N. Gray, J. Lim, R.D. Moir, R.E. Tanzi and A.I. Bush, The Abeta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction, Biochemistry 38 (1999), 7609-7616.
42. N. Hudson, M. Balsitis, S. Everitt and C.J. Hawkey, Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs, Gut 34 (1993), 742-747.
43. B.A. in t'Veld, A. Ruitenberg, A. Hofman, L.J. Launer, C.M. van Duijn, T. Stijnen, M.M. Breteler and B.H. Stricker, Nonsteroidal anti-inflammatory drugs and risk of Alzheimer's disease, N Engl J Med 345 (2001), 1515-1521.
44. C. Jiang, A.T. Ting and B. Seed, PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines, Nature 391 (1998), 82-86.
45. H. Jiang, D. Burdick, C.G. Glabe, C.W. Cotman and AJ. Tenner, Beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain, J Immunol 152 (1994), 5050-5059.
46. J.Y. Jouzeau, B. Terlain, A. Abid, E. Nedelec and P. Netter, Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs, Drugs 53 (1997), 563-582.
47. M.I. Kamboh, D.K. Sanghera, R.E. Ferrell and S.T. DeKosky, APOE-4-associated Alzheimer's disease risk is modified by alpha 1-antichymotrypsin polymorphism, Nat Genet 10 (1995), 486-488.
48. A. Klegeris and P.L. McGeer, Beta-amyloid protein enhances macrophage production of oxygen free radicals and glutamate, J Neurosci Res 49 (1997), 229-235.
49. A. Klegeris and P.L. McGeer, Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity, Neurobiol Aging 23 (2002), 787-794.
50. V. Kostic, V. Jackson-Lewis, E de Bilbao, M. Dubois-Dauphin and S. Przedborski, Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis, Science 277 (1997), 559-562.
51. J.Y. Lehtonen, J.M. Holopainen and P.K. Kinnunen, Activation of phospholipase A2 by amyloid beta-peptides in vitro, Biochemistry 35 (1996), 9407-9414.
52. M. Li, V.O. Ona, C. Guegan, M. Chen, V. Jackson-Lewis, L.J. Andrews, A.J. Olszewski, P.E. Stieg, J.P. Lee, S. Przedborski and R.M. Friedlander, Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model, Science 288 (2000), 335-339.
53. Y. Li, L. Liu, J. Kang, J.G. Sheng, S.W. Barger, R.E. Mrak and W.S. Griffin, Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression, J Neurosci 20 (2000), 149-155.
54. G.P. Lim, F. Yang, T. Chu, E. Gahtan, O. Ubeda, W. Beech, J.B. Overmier, K. Hsiao-Ashec, S.A. Frautschy and G.M. Cole, Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice, Neurobiol Aging 22 (2001), 983-991.
55. L.F. Lue, R. Rydel, E.F. Brigham, L.B. Yang, H. Hampel, G.M. Murphy Jr, L. Brachova, S.D. Yan, D.G. Walker, Y. Shen and J. Rogers, Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro, Glia 35 (2001), 72-79.
56. T.J. Lyons, H. Liu, J.J. Goto, A. Nersissian, J.A. Roe, J.A. Graden, C. Cafe, L.M. Ellerby, D.E. Bredesen, E.B. Gralla and J. Valentine, Mutations in copper-zinc superoxide dismutase that cause amyotrophic lateral sclerosis alter the zinc binding site and the redox behavior of the protein, Proc Natl Acad Sci USA 93 (1996), 12240-12244.
57. I.R. Mackenzie and D.G. Munoz, Nonsteroidal antiinflammatory drug use and Alzheimer-type pathology in aging, Neurology 50 (1998), 986-990.
58. H. Manev, T. Uz, K. Sugaya and T. Qu, Putative role of neuronal 5-lipoxygenase in an aging brain, FASEB J 14 (2000), 1464-1469.
59. W.R. Markesbery and J.M. Carney, Oxidative alterations in Alzheimer's disease, Brain Pathol 9 (1999), 133-146.
60. D.R. McDonald, K.R. Brunden and G.E. Landreth, Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia, J Neurosci 17 (1997), 2284-2294.
61. P.L. McGeer, H. Aldyama, S. Itagaki and E.G. McGeer, Activation of the classical complement pathway in brain tissue of Alzheimer patients, Neurosci Lett 107 (1989), 341-346.
62. P.L. McGeer, H. Akiyama, S. Itagaki and E.G. McGeer, Immune system response in Alzheimer's disease, Can J Neurol Sci 16 (1989), 516-527.
63. P.L. McGeer, S. Itagaki, H. Tago and E.G. McGeer, Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR, Neurosci Lett 79 (1987), 195-200.
64. P.L. McGeer, E.G. McGeer, J. Rogers and J. Sibley, Antiinflammatory drugs and Alzheimer's disease, Lancet 335 (1990), 1037.
65. P.L. McGeer, M. Schulzer and E.G. McGeer, Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies, Neurology 47 (1996), 425-432.
66. S.M. McCusker, M.D. Curran, K.B. Dynan, C.D. McCullagh, D.D. Urquhart, D. Middleton, C.C. Patterson, S.P. McIlroy and A.P. Passmore, Association between polymorphism in regulatory region of gene encoding tumour necrosis factor alpha and risk of Alzheimer's disease and vascular dementia: a case-control study, Lancet 357 (2001), 436-439.
67. L. Meda, P. Baron and G. Scarlato, Glial activation in Alzheimer's disease: the role of Abeta and its associated proteins, Neurobiol Aging 22 (2001), 885-893.
68. L. Meda, S. Bernasconi, C. Bonaiuto, S. Sozzani, D. Zhou, L. Otvos Jr, A. Mantovani, F. Rossi and M.A. Cassatella, Beta-amyloid (25-35) peptide and IFN-gamma synergistically induce the production of the chemotactic cytokine MCP-1/JE in monocytes and microglial cells, J Immunol 157 (1996), 1213-1218.
69. J.A. Nicoll, R.E. Mrak, D.I. Graham, J. Stewart, G. Wilcock, S. MacGowan, M.M. Esiri, L.S. Murray, D. Dewar, S. Love, T. Moss and W.S. Griffin, Association of interleukin-1 gene polymorphisms with Alzheimer's disease, Ann Neurol 47 (2000), 365-368.
70. A. Papassotiropoulos, M. Bagli, F. Jessen, T.A. Bayer, W. Maier, M.L. Rao and R. Heun, A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease, Ann Neurol 45 (1999), 666-668.
71. R.K. Phul, P.J. Shaw, P.G. Ince and M.E. Smith, Expression of nitric oxide synthase isoforms in spinal cord in amyotrophic lateral sclerosis, Amyotroph Lateral Scler Other Motor Neuron Disord 1 (2000), 259-267.
72. P.N. Pompl, L. Ho, M. Bianchi, T. Mcmanus, W. Gin and G.M. Pasinetti, A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis, The FASEB Journal 17 (2003), 725-727.
73. A. Pramatarova, J. Laganiere, J. Roussel, K. Brisebois and G.A. Rouleau, Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment, J Neurosci 21 (2001), 3369-3374.
74. X. Qiao, D.J. Cummins and S.M. Paul, Neuroinflammation-induced acceleration of amyloid deposition in the APPV717F transgenic mouse, Eur J Neurosci 14 (2001), 474-482.
75. L. Qin, Y. Liu, C. Cooper, B. Liu, B. Wilson and J.S. Hong, Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species, J Neurochem 83 (2002), 973-983.
76. T. Qu, R. Manev and H. Manev, 5-Lipoxygenase (5-LOX) promoter polymorphism in patients with early-onset and late-onset Alzheimer's disease, J Neuropsychiatry Clin Neurosci 13 (2001), 304-305.
77. J.B. Rich, D.X. Rasmusson, M.F. Folstein, K.A. Carson, C. Kawas and J. Brandt, Nonsteroidal anti-inflammatory drugs in Alzheimer's disease, Neurology 45 (1995), 51-55.
78. K.A. Robinson, C.A. Stewart, Q.N. Pye, X. Nguyen, L. Kenney, S. Salzman, R.A. Floyd and K. Hensley, Redox-sensitive protein phosphatase activity regulates the phosphorylation state of p38 protein kinase in primary astrocyte culture, J Neurosci Res 55 (1999), 724-732.
79. J. Rogers, N.R. Cooper, S. Webster, J. Schultz, P.L. McGeer, S.D. Styren, W.H. Civin, L. Brachova, B. Bradt and P. Ward, Complement activation by beta-amyloid in Alzheimer disease, Proc Natl Acad Sci USA 89 (1992), 10016-10020.
80. J. Rogers, L.C. Kirby, S.R. Hempelman, D.L. Berry, P.L. McGeer, A.W. Kaszniak, J. Zalinski, M. Cofield, L. Mansukhani and P. Willson, Clinical trial of indomethacin in Alzheimer's disease, Neurology 43 (1993), 1609-1611.
81. C. Rozenfeld, R. Martinez, R.T. Figueiredo, M.T. Bozza, F.R. Lima, A.L. Pires, P.M. Silva, A. Bonomo, J. Lannes-Vieira, W. De Souza and V. Moura-Neto, Soluble factors released by Toxoplasma gondii-infected astrocytes down-modulate nitric oxide production by gamma interferon-activated microglia and prevent neuronal degeneration, Infect Immun 71 (2003), 2047-2057.
82. S. Sainati, D. Ingram, G. Talwalker and G. Geis, Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy, Stockholm, April 2000.
83. A. Sala, S. Zarini and M. Bolla, Leukotrienes: lipid bioeffectors of inflammatory reactions, Biochemistry (Mosc) 63 (1998), 84-92.
84. H. Salari, P. Braquet and P. Borgeat, Comparative effects of indomethacin, acetylenic acids, 15-HETE, nordihydroguaiaretic acid, and BW755C on the metabolism of arachidonic acid in human leukocytes and platelets, Prostaglandins Leukot Med 13 (1984), 53-60.
85. M. Sastre, I. Dewachter, G.E. Landreth, T.M. Willson, T. Klockgether, F. van Leuven and M.T. Heneka, Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase, J Neurosci 23 (2003), 9796-9804.
86. S. Scharf, A. Mander, A. Ugoni, F. Vajda and N. Christophidis, A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease, Neurology 53 (1999), 197-201.
87. Y. Shen, L. Lue, L. Yang, A. Roher, Y. Kuo, R. Strohmeyer, W.J. Goux, V. Lee, G.V. Johnson, S.D. Webster, N.R. Cooper, B. Bradt and J. Rogers, Complement activation by neurofibrillary tangles in Alzheimer's disease, Neurosci Lett 305 (2001), 165-168.
88. J.G. Sheng, S.H. Bora, G. Xu, D.R. Borchelt, D.L. Price and V.E. Koliatsos, Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APP-swe transgenic mice, Neurobiol Dis 14 (2003), 133-145.
89. Y. Shishido, M. Furushiro, S. Hashimoto and T. Yokokura, Effect of nordihydroguaiaretic acid on behavioral impairment and neuronal cell death after forebrain ischemia, Pharmacol Biochem Behav 69 (2001), 469-474.
90. E. Skrzypczak-Jankun, N.P. McCabe, S.H. Selman and J. Jankun, Curcumin inhibits lipoxygenase by binding to its central cavity: Theoretical and X-ray evidence, Int J Mol Med 6 (2000), 521-526.
91. W.F. Stewart, C. Kawas, M. Corrada and E.J. Metter, Risk of Alzheimer's disease and duration of NSAID use, Neurology 48 (1997), 626-632.
92. J.H. Su, G. Deng and C.W. Cotman, Neuronal DNA damage precedes tangle formation and is associated with upregulation of nitrotyrosine in Alzheimer's disease brain, Brain Res 774 (1997), 193-199.
93. K. Sugaya, T. Uz, V. Kumar and H. Manev, New antiinflammatory treatment strategy in Alzheimer's disease, Jpn J Pharmacol 82 (2000), 85-94.
94. E. Tamagno, M. Parola, M. Guglielmotto, G. Santoro, P. Bardini, L. Marra, M. Tabaton and O. Danni, Multiple signaling events in amyloid beta-induced, oxidative stress-dependent neuronal apoptosis, Free Radic Biol Med 35 (2003), 45-58.
95. E. Tarkowski, K. Blennow, A. Wallin and A. Tarkowski, Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia, J Clin Immunol 19 (1999), 223-230.
96. H. Tohgi, T. Abe, K. Yamazaki, T. Murata, E. Ishizaki and C. Isobe, Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis, Ann Neurol 46 (1999), 129-131.
97. T. Uz, C. Pesold, P. Longone and H. Manev, Aging associated up-regulation of neuronal 5-lipoxygenase expression: Putative role in neuronal vulnerability, FASEB J 12 (1998), 439-449.
98. E.A. van der Wal, F. Gomez-Pinnilla and C.W. Cotman, Transforming growth factor-beta lis in plaques in Alzheimer's and Down pathologies, Neuroreport 4 (1993), 69-72.
99. EL. Van Muiswinkel, R. Veerhuis and P. Eikelenboom, Amyloid beta protein primes cultured rat microglial cells for an enhanced phorbol 12-myristate 13-acetate-induced respiratory burst activity, J Neurochem 66 (1996), 2468-2476.
100. S. Webster, B. Bonnell and J. Rogers, Charge-based binding of complement component Clq to the Alzheimer amyloid beta-peptide, Am J Pathol 150 (1997), 1531-1536.
101. S. Weggen, J.L. Eriksen, P. Das, S.A. Sagi, R. Wang, C.U. Pietrzik, K.A. Findlay, T.E. Smith, M.P. Murphy, T. Bulter, D.E. Kang, N. Marquez-Sterling, T.E. Golde and E.H. Koo, A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity, Nature 414 (2001), 212-216.
102. G.L. Wenk, K. McGann, B. Hauss-Wegrzyniak and S. Rosi, The toxicity of tumor necrosis factor-alpha upon cholinergic neurons within the nucleus basalis and the role of norepinephrine in the regulation of inflammation: implications for Alzheimer's disease, Neuroscience 121 (2003), 719-729.
103. S. Whitman, M. Gezginci, B.N. Timmermann and T.R. Holman, Structure-activity relationship studies of nordihydroguaiaretic acid inhibitors toward soybean 12-human and 15-human lipoxygenase, J Med Chem 45 (2002), 2659-2666.
104. A. Wong, S. Dukic-Stefanovic, J. Gasic-Milenkovic, R. Schinzel, H. Wiesinger, P. Riederer and G. Munch, Antiinflammatory antioxidants attenuate the expression of inducible nitric oxide synthase mediated by advanced glycation endproducts in murine microglia, Eur J Neurosci 14 (2001), 1961-1967.
105. C.H. Woo, Y.W. Eom, M.H. Yoo, H.J. You, H.J. Han, W.K. Song, Y.J. Yoo, J.S. Chun and J.H. Kim, Tumor necrosis factor alpha generates reactive oxygen species via a cytosolic phospholipase A2-linked cascade, J Biol Chem 275 (2000), 32357-32362.
106. T. Wyss-Coray, C. Lin, D. von Euw, E. Masliah, L. Mucke and P. Lacombe, Alzheimer's disease-like cerebrovascular pathology in transforming growth factor-beta 1 transgenic mice and functional metabolic correlates, Ann N Y Acad Sci 903 (2000), 317-323.
107. K. Yamamoto, T. Arakawa, N. Ueda and S. Yamamoto, Transcriptional Roles of Nuclear Factor B and Nuclear Factor-Interleukin-6 in the Tumor Necrosis Factor-Dependent Inducoon of Cyclooxygenase-2 in MC3T3-E1 Cells, J Biol Chem 270 (1995), 31315-31320.
108. Q. Yan, J. Zhang, H. Liu, S. Babu-Khan, R. Vassar, A.L. Biere, M. Citron and Landreth, Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease, J Neurosci 23 (2003), 7504-7509.
109. M.B. Yim, J.H. Kang, H.S. Yim, H.S. Kwak, P.B. Chock and E.R. Stadtman, A gain-of-function of an amyotrophic lateral sclerosis-associated Cu, Zn-superoxide dismutase mutant: An enhancement of free radical formation due to a decrease in Km for hydrogen peroxide, Proc Natl Acad Sci USA 93 (1996), 5709-5714.
110. T. Yoshihara, S. Ishigaki, M. Yamamoto, Y. Liang, J. Niwa, H. Takeuchi, M. Doyu and G. Sobue, Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis, J Neurochem 80 (2002), 158-167.
111. M. Zhao, D.H. Cribbs, A.J. Anderson, B.J. Cummings, J.H. Su, A.J. Wasserman and C.W. Cotman, The induction of the TNFalpha death domain-signaling pathway in Alzheimer's disease brain, Neurochem Res 28 (2003), 307-318.